Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as ...

BioNTech SE (NASDAQ:BNTX) and Bristol Myers (NYSE:BMY) Squibb have announced their global collaboration for the co-development and co-commercialization of BioNTech’s experimental bispecific antibody ...

A university research team is exploring a new way to treat a widespread but often undetected liver disease affecting millions ...

Bristol Myers Squibb is partnering with BioNTech on a closely watched cancer drug, in a deal worth billions of dollars.

Treating women with hormone receptor–positive, HER2-negative breast cancer using AstraZeneca’s (NASDAQ: AZN) experimental ...

PARIS] Sanofi agreed to buy Blueprint Medicines for at least US$9.1 billion as the French drugmaker expands further in rare ...

Sree Chitra Tirunal Institute for Medical Sciences (SCTIMST) has transferred 6 technologies to the industry during this year.

AstraZeneca Plc’s experimental breast cancer pill delayed disease progression by over six months, according to data from a ...

The health sector sees dynamic shifts with Thailand's poultry industry set for growth, breakthrough breast cancer treatments ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...